Literature DB >> 25638331

ABO blood group in primary antiphospholipid syndrome: influence in the site of thrombosis?

Natália Mastantuono Nascimento1, Sergio Paulo Bydlowski, Rosangela Paula Silva Soares, Danieli Castro Oliveira de Andrade, Eloísa Bonfá, Luciana Parente Costa Seguro, Eduardo Ferreira Borba.   

Abstract

Antiphospholipid syndrome (APS) is characterized by vascular thrombosis and/or obstetric complications associated with presence of antiphospholipid antibodies (aPL) but additional factors would also induce thrombosis. ABO (H) blood groups are known to be closely related to thrombosis, especially non-O blood type with venous events. The aim of this study was to investigate possible role of ABO (H) blood types in the thrombotic events in primary APS (PAPS). Seventy PAPS patients were selected for the study and were divided according to ABO blood group in: O PAPS (n = 26) and non-O PAPS (n = 44). ABO blood group phenotyping was performed by indirect technique. aPL anticardiolipin (aCL) and anti-βeta2 glycoprotein-1 (aβ2GPI) and the concentrations and activities of von Willebrand factor (VWF) were measured with ELISA. Lupus anticoagulant (LA) was detected by coagulation assays. A significant higher frequency of venous events was observed in non-O PAPS group (72.7 vs. 46.2 %, p = 0.040). In contrast, the frequency of arterial events was significantly higher in the O PAPS compared to the non-O PAPS group (69.2 vs. 36.4 %, respectively; p = 0.013). Frequencies of aCL, LA, aβ2GPI and triple aPL positivity were similar in both groups (p > 0.05). VWF antigen (75.54 ± 8.68 vs. 79.51 ± 7.07 IU/dl, p = 0.041) and activity (70.23 ± 11.96 vs. 77.92 ± 13.67 %, p = 0.020) were decreased in O PAPS compared to non-O blood group. VWF:CB/VWF:Ag ratio was similar among groups (p > 0.05). This is the first report that confirms the role of ABO blood system in thrombosis of PAPS and suggests that non-O blood group was related with venous events and O blood group with arterial thrombosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25638331     DOI: 10.1007/s11239-015-1176-8

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  30 in total

1.  Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study.

Authors:  A Ruffatti; T Del Ross; M Ciprian; M Nuzzo; M Rampudda; M T Bertero; R Bergia; P Caramaschi; D Biasi; F Capsoni; L Montaguti; R Ruffini; A Brucato; U Picillo; V Fanelli; V Riccieri; A Piccoli; G Valesini; A Doria; P L Meroni; A Tincani
Journal:  Ann Rheum Dis       Date:  2008-09-23       Impact factor: 19.103

2.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

3.  von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis.

Authors:  A Y Nossent; V VAN Marion; N H VAN Tilburg; F R Rosendaal; R M Bertina; J A VAN Mourik; H C J Eikenboom
Journal:  J Thromb Haemost       Date:  2006-10-16       Impact factor: 5.824

Review 4.  Pathogenesis of antiphospholipid syndrome: understanding the antibodies.

Authors:  Pier Luigi Meroni; M Orietta Borghi; Elena Raschi; Francesco Tedesco
Journal:  Nat Rev Rheumatol       Date:  2011-05-10       Impact factor: 20.543

Review 5.  Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature.

Authors:  Francesco Dentali; Anna Paola Sironi; Walter Ageno; Sara Turato; Carlo Bonfanti; Francesco Frattini; Silvia Crestani; Massimo Franchini
Journal:  Semin Thromb Hemost       Date:  2012-06-27       Impact factor: 4.180

6.  Abnormalities in circulating von Willebrand factor and survival in pulmonary hypertension.

Authors:  A A Lopes; N Y Maeda; S P Bydlowski
Journal:  Am J Med       Date:  1998-07       Impact factor: 4.965

7.  An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13.

Authors:  D J Bowen
Journal:  J Thromb Haemost       Date:  2003-01       Impact factor: 5.824

8.  Reduced prevalence of arterial thrombosis in von Willebrand disease.

Authors:  Y V Sanders; J Eikenboom; E M de Wee; J G van der Bom; M H Cnossen; M E L Degenaar-Dujardin; K Fijnvandraat; P W Kamphuisen; B A P Laros-van Gorkom; K Meijer; E P Mauser-Bunschoten; F W G Leebeek
Journal:  J Thromb Haemost       Date:  2013-05       Impact factor: 5.824

9.  ABO blood group, other risk factors and incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE).

Authors:  T Ohira; M Cushman; M Y Tsai; Y Zhang; S R Heckbert; N A Zakai; W D Rosamond; A R Folsom
Journal:  J Thromb Haemost       Date:  2007-04-09       Impact factor: 5.824

10.  Changes of von Willebrand Factor during Pregnancy in Women with and without von Willebrand Disease.

Authors:  Giancarlo Castaman
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-07-16       Impact factor: 2.576

View more
  1 in total

1.  Impact of Classical Risk Factors for Arterial or Venous Thrombosis in Patients With Antiphospholipid Syndrome.

Authors:  Daniel Navarro-Carpentieri; Maria Del Carmen Castillo-Hernandez; Karim Majluf-Cruz; Guillermo Espejo-Godinez; Paola Carmona-Olvera; Manuel Moreno-Hernandez; Yolanda Lugo-García; Jesús Hernandez-Juarez; Luis Loarca-Piña; Irma Isordia-Salas; Abraham Majluf-Cruz
Journal:  Clin Appl Thromb Hemost       Date:  2017-09-08       Impact factor: 2.389

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.